Kellerhals Carrard with Panakes Partners in series B financing round

Kellerhals Carrard advised Panakes Partners in leading the EUR 17.9 million Series B financing round of Lymphatica Medtech. This round was co-led by TechWald Holding S.p.A., and CDP Venture Capital SGR, with participation from OCCIDENT, Zürcher Kantonalbank, and Club degli Investitori. Existing investors, including HTGF | High-Tech Gründerfonds, also participated in this round.

Kellerhals Carrard’s team

The Kellerhals Carrard team was co-led by VC/M&A partner Karim Maizar (pictured left) and VC/M&A senior associate Umberto Milano (pictured right) and further included Céline Schmid (senior associate, employment), Eliane Haas (senior associate, IP), Arnault Eckert (associate, VC/M&A) and Céline Reust (trainee).

This investment will accelerate the clinical development and validation of LymphoDrain, a breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions worldwide.